Skip to main content
Top
Published in: CNS Drugs 12/2011

01-12-2011 | Therapy In Practice

Pharmacological Management of Acute and Persistent Aggression in Forensic Psychiatry Settings

Authors: Dr Leslie Citrome, MD, MPH, Jan Volavka

Published in: CNS Drugs | Issue 12/2011

Login to get access

Abstract

Aggressive behaviour is common in forensic psychiatric settings. The aetiology of aggressive behaviour is multifactorial and can be driven by psychosis, impulsivity, psychopathy, intoxication, cognitive impairment, or a combination of all of these. Recognition of the different factors behind the aggression can inform medication selection and the relative need for specific environmental and behavioural interventions in a forensic psychiatric setting. Acute agitation needs to be managed quickly and effectively before further escalation of the behavioural dyscontrol occurs. Benzodiazepines and/or antipsychotic medications are often used and can be given intramuscularly to achieve a rapid onset of action. Available are intramuscular preparations of second-generation antipsychotics that have similar efficacy to lorazepam and haloperidol in reducing agitation, but are well tolerated and not associated with the extrapyramidal adverse effects, including akathisia, that can plague the older first-generation antipsychotics. The longer-term management of persistent aggressive behaviour can be quite complex. A major obstacle is that the causality of aggressive events can differ from patient to patient, and also from event to event in the same patient. For patients with schizophrenia and persistent aggressive behaviour, clozapine is recommended both for its superior antipsychotic effect and its specific anti-hostility effect. Mood stabilizers such as valproate may be helpful in instances of poor impulsivity and personality disorders. Other agents that have been successfully used include β-adrenoceptor antagonists (β-blockers) and antidepressants.
Literature
1.
go back to reference Citrome L, Volavka J. Treatment of violent behavior. In: Tasman A, Lieberman J, Kay J, editors. Psychiatry. 2nd ed. Chichester: John Wiley and Sons, 2003 Citrome L, Volavka J. Treatment of violent behavior. In: Tasman A, Lieberman J, Kay J, editors. Psychiatry. 2nd ed. Chichester: John Wiley and Sons, 2003
2.
go back to reference Volavka J, Citrome L. Heterogeneity of violence in schizophrenia and implications for long-term treatment. Int J Clin Pract 2008; 62(8): 1237–45PubMedCrossRef Volavka J, Citrome L. Heterogeneity of violence in schizophrenia and implications for long-term treatment. Int J Clin Pract 2008; 62(8): 1237–45PubMedCrossRef
3.
go back to reference Salzman C. Use of benzodiazepines to control disruptive behavior in inpatients. J Clin Psychiatry 1988; 49(12 Suppl. ): 13–5PubMed Salzman C. Use of benzodiazepines to control disruptive behavior in inpatients. J Clin Psychiatry 1988; 49(12 Suppl. ): 13–5PubMed
4.
go back to reference Greenblatt DJ, Shader RI, Franke K, et al. Pharmacokinetics and bioavailability of intravenous, intramuscular, and oral lorazepam in humans. J Pharm Sci 1979; 68(1): 57–63PubMedCrossRef Greenblatt DJ, Shader RI, Franke K, et al. Pharmacokinetics and bioavailability of intravenous, intramuscular, and oral lorazepam in humans. J Pharm Sci 1979; 68(1): 57–63PubMedCrossRef
5.
go back to reference Greenblatt DJ, Divoll M, Harmatz JS, et al. Pharmacokinetic comparison of sublingual lorazepam with intravenous, intramuscular, and oral lorazepam. J Pharm Sci 1982; 71(2): 248–52PubMedCrossRef Greenblatt DJ, Divoll M, Harmatz JS, et al. Pharmacokinetic comparison of sublingual lorazepam with intravenous, intramuscular, and oral lorazepam. J Pharm Sci 1982; 71(2): 248–52PubMedCrossRef
6.
go back to reference Ahmed U, Jones H, Adams CE. Chlorpromazine for psychosis induced aggression or agitation. Cochrane Database Syst Rev 2010 Apr 14; (4): CD007445 Ahmed U, Jones H, Adams CE. Chlorpromazine for psychosis induced aggression or agitation. Cochrane Database Syst Rev 2010 Apr 14; (4): CD007445
7.
go back to reference Man PL, Chen CH. Rapid tranqulization of acutely psychotic patients with intramuscular haloperidol and chlorpromazine. Psychosomatics 1973; 14(1): 59–63PubMed Man PL, Chen CH. Rapid tranqulization of acutely psychotic patients with intramuscular haloperidol and chlorpromazine. Psychosomatics 1973; 14(1): 59–63PubMed
8.
go back to reference Battaglia J, Moss S, Rush J, et al. Haloperidol, lorazepam, or both for psychotic agitation? A multicenter, prospective, double-blind, emergency department study. Am J Emerg Med 1997; 15(4): 335–40PubMedCrossRef Battaglia J, Moss S, Rush J, et al. Haloperidol, lorazepam, or both for psychotic agitation? A multicenter, prospective, double-blind, emergency department study. Am J Emerg Med 1997; 15(4): 335–40PubMedCrossRef
9.
go back to reference Huf G, Alexander J, Allen MH, et al. Haloperidol plus promethazine for psychosis-induced aggression. Cochrane Database Syst Rev 2009 Jul 8; (3): CD005146 Huf G, Alexander J, Allen MH, et al. Haloperidol plus promethazine for psychosis-induced aggression. Cochrane Database Syst Rev 2009 Jul 8; (3): CD005146
10.
go back to reference Citrome L. Comparison of intramuscular ziprasidone, olanzapine, or aripiprazole for agitation: a quantitative review of efficacy and safety. J Clin Psychiatry 2007; 68(12): 1876–85PubMedCrossRef Citrome L. Comparison of intramuscular ziprasidone, olanzapine, or aripiprazole for agitation: a quantitative review of efficacy and safety. J Clin Psychiatry 2007; 68(12): 1876–85PubMedCrossRef
11.
go back to reference Lesem MD, Zajecka JM, Swift RH, et al. Intramuscular ziprasidone, 2 mg versus 10 mg, in the short-term management of agitated psychotic patients. J Clin Psychiatry 2001; 62(1): 12–8PubMedCrossRef Lesem MD, Zajecka JM, Swift RH, et al. Intramuscular ziprasidone, 2 mg versus 10 mg, in the short-term management of agitated psychotic patients. J Clin Psychiatry 2001; 62(1): 12–8PubMedCrossRef
12.
go back to reference Daniel DG, Potkin SG, Reeves KR, et al. Intramuscular (IM) ziprasidone 20 mg is effective in reducing acute agitation associated with psychosis: a double-blind, randomized trial. Psychopharmacology (Berl) 2001; 155(2): 128–34CrossRef Daniel DG, Potkin SG, Reeves KR, et al. Intramuscular (IM) ziprasidone 20 mg is effective in reducing acute agitation associated with psychosis: a double-blind, randomized trial. Psychopharmacology (Berl) 2001; 155(2): 128–34CrossRef
13.
go back to reference Preval H, Klotz SG, Southard R, et al. Rapid-acting IM ziprasidone in a psychiatric emergency service: a naturalistic study. Gen Hosp Psychiatry 2005; 27(2): 140–4PubMedCrossRef Preval H, Klotz SG, Southard R, et al. Rapid-acting IM ziprasidone in a psychiatric emergency service: a naturalistic study. Gen Hosp Psychiatry 2005; 27(2): 140–4PubMedCrossRef
15.
go back to reference Wright P, Birkett M, David SR, et al. Double-blind, placebo-controlled comparison of intramuscular olanzapine and intramuscular haloperidol in the treatment of acute agitation in schizophrenia. Am J Psychiatry 2001; 158(7): 1149–51PubMedCrossRef Wright P, Birkett M, David SR, et al. Double-blind, placebo-controlled comparison of intramuscular olanzapine and intramuscular haloperidol in the treatment of acute agitation in schizophrenia. Am J Psychiatry 2001; 158(7): 1149–51PubMedCrossRef
16.
go back to reference Breier A, Meehan K, Birkett M, et al. A double-blind, placebo-controlled dose-response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia. Arch Gen Psychiatry 2002; 59(5): 441–8PubMedCrossRef Breier A, Meehan K, Birkett M, et al. A double-blind, placebo-controlled dose-response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia. Arch Gen Psychiatry 2002; 59(5): 441–8PubMedCrossRef
17.
go back to reference Meehan K, Zhang F, David S, et al. A double-blind, randomized comparison of the efficacy and safety of intramuscular injections of olanzapine, lorazepam, or placebo in treating acutely agitated patients diagnosed with bipolar mania. J Clin Psychopharmacol 2001; 21(4): 389–97PubMedCrossRef Meehan K, Zhang F, David S, et al. A double-blind, randomized comparison of the efficacy and safety of intramuscular injections of olanzapine, lorazepam, or placebo in treating acutely agitated patients diagnosed with bipolar mania. J Clin Psychopharmacol 2001; 21(4): 389–97PubMedCrossRef
18.
go back to reference Eli Lilly and Co. Zyprexa (olanzapine) tablets, Zyprexa Zydis (olanzapine) orally disintegrating tablets, Zyprexa IntraMuscular (olanzapine) for injection: product information revised June 2011 [online]. Available from URL: http://pi.lilly.com/us/zyprexa-pi.pdf. [Accessed 2011 Jul 17] Eli Lilly and Co. Zyprexa (olanzapine) tablets, Zyprexa Zydis (olanzapine) orally disintegrating tablets, Zyprexa IntraMuscular (olanzapine) for injection: product information revised June 2011 [online]. Available from URL: http://​pi.​lilly.​com/​us/​zyprexa-pi.​pdf. [Accessed 2011 Jul 17]
19.
go back to reference San L, Arranz B, Querejeta I, et al. A naturalistic multicenter study of intramuscular olanzapine in the treatment of acutely agitated manic or schizophrenic patients. Eur Psychiatry 2006; 21(8): 539–43PubMedCrossRef San L, Arranz B, Querejeta I, et al. A naturalistic multicenter study of intramuscular olanzapine in the treatment of acutely agitated manic or schizophrenic patients. Eur Psychiatry 2006; 21(8): 539–43PubMedCrossRef
20.
go back to reference Marder SR, Sorsaburu S, Dunayevich E, et al. Case reports of postmarketing adverse event experiences with olanzapine intramuscular treatment in patients with agitation. J Clin Psychiatry 2010; 71(4): 433–41PubMedCrossRef Marder SR, Sorsaburu S, Dunayevich E, et al. Case reports of postmarketing adverse event experiences with olanzapine intramuscular treatment in patients with agitation. J Clin Psychiatry 2010; 71(4): 433–41PubMedCrossRef
21.
go back to reference Andrezina R, Josiassen RC, Marcus RN, et al. Intramuscular aripiprazole for the treatment of acute agitation in patients with schizophrenia or schizoaffective disorder: a double-blind, placebo-controlled comparison with intramuscular haloperidol. Psychopharmacology (Berl) 2006; 188(3): 281–92CrossRef Andrezina R, Josiassen RC, Marcus RN, et al. Intramuscular aripiprazole for the treatment of acute agitation in patients with schizophrenia or schizoaffective disorder: a double-blind, placebo-controlled comparison with intramuscular haloperidol. Psychopharmacology (Berl) 2006; 188(3): 281–92CrossRef
22.
go back to reference Tran-Johnson TK, Sack DA, Marcus RN, et al. Efficacy and safety of intramuscular aripiprazole in patients with acute agitation: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2007; 68(1): 111–9PubMedCrossRef Tran-Johnson TK, Sack DA, Marcus RN, et al. Efficacy and safety of intramuscular aripiprazole in patients with acute agitation: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2007; 68(1): 111–9PubMedCrossRef
23.
go back to reference Zimbroff DL, Marcus RN, Manos G, et al. Management of acute agitation in patients with bipolar disorder: efficacy and safety of intramuscular aripiprazole. J Clin Psychopharmacol 2007; 27(2): 171–6PubMedCrossRef Zimbroff DL, Marcus RN, Manos G, et al. Management of acute agitation in patients with bipolar disorder: efficacy and safety of intramuscular aripiprazole. J Clin Psychopharmacol 2007; 27(2): 171–6PubMedCrossRef
24.
go back to reference Bristol-Myers Squibb. Abilify (aripiprazole) tablets, Abilify (aripiprazole) DiscMelt orally disintegrating tablets, Abilify (aripiprazole) oral solution, Abilify (aripiprazole) injection for intramuscular use only: product information revised February 2011 [online]. Available from URL: http://www.abilify.com/pdf/pi.aspx [Accessed 2011 Jul 17] Bristol-Myers Squibb. Abilify (aripiprazole) tablets, Abilify (aripiprazole) DiscMelt orally disintegrating tablets, Abilify (aripiprazole) oral solution, Abilify (aripiprazole) injection for intramuscular use only: product information revised February 2011 [online]. Available from URL: http://​www.​abilify.​com/​pdf/​pi.​aspx [Accessed 2011 Jul 17]
25.
go back to reference Citrome L. Aerosolised antipsychotic assuages agitation: inhaled loxapine for agitation associated with schizophrenia or bipolar disorder. Int J Clin Pract 2011; 65(3): 330–40PubMedCrossRef Citrome L. Aerosolised antipsychotic assuages agitation: inhaled loxapine for agitation associated with schizophrenia or bipolar disorder. Int J Clin Pract 2011; 65(3): 330–40PubMedCrossRef
26.
go back to reference Allen MH, Feifel D, Lesem MD, et al. Efficacy and safety of loxapine for inhalation in the treatment of agitation in patients with schizophrenia: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. Epub 2011 Jan 25 Allen MH, Feifel D, Lesem MD, et al. Efficacy and safety of loxapine for inhalation in the treatment of agitation in patients with schizophrenia: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. Epub 2011 Jan 25
27.
go back to reference Lesem MD, Tran-Johnson TK, Riesenberg RA, et al. Rapid acute treatment of agitation in individuals with schizophrenia: multicentre, randomised, placebo-controlled study of inhaled loxapine. Br J Psychiatry 2011; 198(1): 51–8PubMedCrossRef Lesem MD, Tran-Johnson TK, Riesenberg RA, et al. Rapid acute treatment of agitation in individuals with schizophrenia: multicentre, randomised, placebo-controlled study of inhaled loxapine. Br J Psychiatry 2011; 198(1): 51–8PubMedCrossRef
28.
go back to reference Fishman R, Cassella J, Spyker D, AZ-004 Study Group. Inhaled loxapine rapidly improves acute agitation in patients with bipolar disorder [poster presentation, NR7-006]. 162nd Annual Meeting of the American Psychiatric Association; 2009 May 16–21; San Francisco (CA) Fishman R, Cassella J, Spyker D, AZ-004 Study Group. Inhaled loxapine rapidly improves acute agitation in patients with bipolar disorder [poster presentation, NR7-006]. 162nd Annual Meeting of the American Psychiatric Association; 2009 May 16–21; San Francisco (CA)
29.
go back to reference Currier GW, Chou JCY, Feifel D, et al. Acute treatment of psychotic agitation: a randomized comparison of oral treatment with risperidone and lorazepam versus intramuscular treatment with haloperidol and lorazepam. J Clin Psychiatry 2004; 65(3): 386–94PubMedCrossRef Currier GW, Chou JCY, Feifel D, et al. Acute treatment of psychotic agitation: a randomized comparison of oral treatment with risperidone and lorazepam versus intramuscular treatment with haloperidol and lorazepam. J Clin Psychiatry 2004; 65(3): 386–94PubMedCrossRef
30.
go back to reference Baker RW, Kinon BJ, Maguire GA, et al. Effectiveness of rapid initial dose escalation of up to forty milligrams per day of oral olanzapine in acute agitation. J Clin Psychopharmacol 2003; 23(4): 342–8PubMedCrossRef Baker RW, Kinon BJ, Maguire GA, et al. Effectiveness of rapid initial dose escalation of up to forty milligrams per day of oral olanzapine in acute agitation. J Clin Psychopharmacol 2003; 23(4): 342–8PubMedCrossRef
31.
go back to reference Hsu WY, Huang SS, Lee BS, et al. Comparison of intramuscular olanzapine, orally disintegrating olanzapine tablets, oral risperidone solution, and intramuscular haloperidol in the management of acute agitation in an acute care psychiatric ward in Taiwan. J Clin Psychopharmacol 2010; 30(3): 230–4PubMedCrossRef Hsu WY, Huang SS, Lee BS, et al. Comparison of intramuscular olanzapine, orally disintegrating olanzapine tablets, oral risperidone solution, and intramuscular haloperidol in the management of acute agitation in an acute care psychiatric ward in Taiwan. J Clin Psychopharmacol 2010; 30(3): 230–4PubMedCrossRef
32.
go back to reference Villari V, Rocca P, Fonzo V, et al. Oral risperidone, olanzapine and quetiapine versus haloperidol in psychotic agitation. Prog Neuropsychopharmacol Biol Psychiatry 2008; 32(2): 405–13PubMedCrossRef Villari V, Rocca P, Fonzo V, et al. Oral risperidone, olanzapine and quetiapine versus haloperidol in psychotic agitation. Prog Neuropsychopharmacol Biol Psychiatry 2008; 32(2): 405–13PubMedCrossRef
33.
go back to reference Allen MH, Debanné M, Lazignac C, et al. Effect of nicotine replacement therapy on agitation in smokers with schizophrenia: a double-blind, randomized, placebo-controlled study. Am J Psychiatry 2011; 168(4): 395–9PubMedCrossRef Allen MH, Debanné M, Lazignac C, et al. Effect of nicotine replacement therapy on agitation in smokers with schizophrenia: a double-blind, randomized, placebo-controlled study. Am J Psychiatry 2011; 168(4): 395–9PubMedCrossRef
34.
go back to reference Citrome L, Nolan KA, Volavka J. Science-based treatment of aggression and agitation. In: Fishbein D, editor. The science, treatment, and prevention of antisocial behaviors. Vol 2. Kingston (NJ): Civic Research Institute, 2004 Citrome L, Nolan KA, Volavka J. Science-based treatment of aggression and agitation. In: Fishbein D, editor. The science, treatment, and prevention of antisocial behaviors. Vol 2. Kingston (NJ): Civic Research Institute, 2004
35.
go back to reference Haddock G, Barrowclough C, Shaw JJ, et al. Cognitive-behavioural therapy v. social activity therapy for people with psychosis and a history of violence: randomised controlled trial. Br J Psychiatry 2009; 194(2): 152–7 Haddock G, Barrowclough C, Shaw JJ, et al. Cognitive-behavioural therapy v. social activity therapy for people with psychosis and a history of violence: randomised controlled trial. Br J Psychiatry 2009; 194(2): 152–7
36.
go back to reference Yates KF, Kunz M, Khan A, et al. Psychiatric patients with histories of aggression and crime five years after discharge from a cognitive-behavioral program. J Forensic Psychiatry Psychol 2010; 21(2): 167–88CrossRef Yates KF, Kunz M, Khan A, et al. Psychiatric patients with histories of aggression and crime five years after discharge from a cognitive-behavioral program. J Forensic Psychiatry Psychol 2010; 21(2): 167–88CrossRef
37.
go back to reference Nolan KA, Citrome L. Reducing inpatient aggression: does paying attention pay off? Psychiatr Q 2008; 79(2): 91–5PubMedCrossRef Nolan KA, Citrome L. Reducing inpatient aggression: does paying attention pay off? Psychiatr Q 2008; 79(2): 91–5PubMedCrossRef
38.
go back to reference Leucht S, Corves C, Arbter D, et al. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 2009; 373(9657): 31–41PubMedCrossRef Leucht S, Corves C, Arbter D, et al. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 2009; 373(9657): 31–41PubMedCrossRef
39.
go back to reference Leucht S, Komossa K, Rummel-Kluge C, et al. A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. Am J Psychiatry 2009; 166(2): 152–63PubMedCrossRef Leucht S, Komossa K, Rummel-Kluge C, et al. A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. Am J Psychiatry 2009; 166(2): 152–63PubMedCrossRef
40.
go back to reference Citrome L. A systematic review of meta-analyses of the efficacy of oral atypical antipsychotics for the treatment of adult patients with schizophrenia. Exp Opin Pharmacotherapy. In press Citrome L. A systematic review of meta-analyses of the efficacy of oral atypical antipsychotics for the treatment of adult patients with schizophrenia. Exp Opin Pharmacotherapy. In press
41.
go back to reference Volavka J, Zito JM, Vitrai J, et al. Clozapine effects on hostility and aggression in schizophrenia. J Clin Psychopharmacol 1993; 13(4): 287–9PubMedCrossRef Volavka J, Zito JM, Vitrai J, et al. Clozapine effects on hostility and aggression in schizophrenia. J Clin Psychopharmacol 1993; 13(4): 287–9PubMedCrossRef
42.
go back to reference Citrome L, Volavka J, Czobor P, et al. Effects of clozapine, olanzapine, risperidone, and haloperidol on hostility among patients with schizophrenia. Psychiatr Serv 2001; 52(11): 1510–4PubMedCrossRef Citrome L, Volavka J, Czobor P, et al. Effects of clozapine, olanzapine, risperidone, and haloperidol on hostility among patients with schizophrenia. Psychiatr Serv 2001; 52(11): 1510–4PubMedCrossRef
43.
go back to reference Volavka J, Czobor P, Nolan K, et al. Overt aggression and psychotic symptoms in patients with schizophrenia treated with clozapine, olanzapine, risperidone, or haloperidol. J Clin Psychopharmacol 2004; 24(2): 225–8PubMedCrossRef Volavka J, Czobor P, Nolan K, et al. Overt aggression and psychotic symptoms in patients with schizophrenia treated with clozapine, olanzapine, risperidone, or haloperidol. J Clin Psychopharmacol 2004; 24(2): 225–8PubMedCrossRef
44.
go back to reference Krakowski MI, Czobor P, Citrome L, et al. Atypical antipsychotic agents in the treatment of violent patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry 2006; 63(6): 622–9PubMedCrossRef Krakowski MI, Czobor P, Citrome L, et al. Atypical antipsychotic agents in the treatment of violent patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry 2006; 63(6): 622–9PubMedCrossRef
45.
go back to reference Maccall C, Billcliff N, Igbrude W, et al. Clozapine: more than 900 mg/day may be needed. J Psychopharmacol 2009; 23(2): 206–10PubMedCrossRef Maccall C, Billcliff N, Igbrude W, et al. Clozapine: more than 900 mg/day may be needed. J Psychopharmacol 2009; 23(2): 206–10PubMedCrossRef
46.
go back to reference Eap CB, Bender S, Jaquenoud SE, et al. Nonresponse to clozapine and ultrarapid CYP1A2 activity: clinical data and analysis of CYP1A2 gene. J Clin Psychopharmacol 2004; 24(2): 214–9PubMedCrossRef Eap CB, Bender S, Jaquenoud SE, et al. Nonresponse to clozapine and ultrarapid CYP1A2 activity: clinical data and analysis of CYP1A2 gene. J Clin Psychopharmacol 2004; 24(2): 214–9PubMedCrossRef
47.
go back to reference Czobor P, Volavka J, Meibach RC. Effect of risperidone on hostility in schizophrenia. J Clin Psychopharmacol 1995; 15(4): 243–9PubMedCrossRef Czobor P, Volavka J, Meibach RC. Effect of risperidone on hostility in schizophrenia. J Clin Psychopharmacol 1995; 15(4): 243–9PubMedCrossRef
48.
go back to reference Kinon BJ, Roychowdhury SM, Milton DR, et al. Effective resolution with olanzapine of acute presentation of behavioral agitation and positive psychotic symptoms in schizophrenia. J Clin Psychiatry 2001; 62 Suppl. 2: 17–21 Kinon BJ, Roychowdhury SM, Milton DR, et al. Effective resolution with olanzapine of acute presentation of behavioral agitation and positive psychotic symptoms in schizophrenia. J Clin Psychiatry 2001; 62 Suppl. 2: 17–21
49.
go back to reference Chengappa KN, Goldstein JM, Greenwood M, et al. A post hoc analysis of the impact on hostility and agitation of quetiapine and haloperidol among patients with schizophrenia. Clin Ther 2003; 25(2): 530–41PubMedCrossRef Chengappa KN, Goldstein JM, Greenwood M, et al. A post hoc analysis of the impact on hostility and agitation of quetiapine and haloperidol among patients with schizophrenia. Clin Ther 2003; 25(2): 530–41PubMedCrossRef
50.
go back to reference Arango C, Bernardo M. The effect of quetiapine on aggression and hostility in patients with schizophrenia. Hum Psychopharmacol 2005; 20(4): 237–41PubMedCrossRef Arango C, Bernardo M. The effect of quetiapine on aggression and hostility in patients with schizophrenia. Hum Psychopharmacol 2005; 20(4): 237–41PubMedCrossRef
51.
go back to reference Citrome L, Volavka J, Czobor P, et al. Efficacy of ziprasidone against hostility in schizophrenia: post hoc analysis of randomized, open-label study data. J Clin Psychiatry 2006; 67(4): 638–42PubMedCrossRef Citrome L, Volavka J, Czobor P, et al. Efficacy of ziprasidone against hostility in schizophrenia: post hoc analysis of randomized, open-label study data. J Clin Psychiatry 2006; 67(4): 638–42PubMedCrossRef
52.
go back to reference Volavka J, Czobor P, Citrome L, et al. Efficacy of aripiprazole against hostility in schizophrenia and schizoaffective disorder: data from 5 double-blind studies. J Clin Psychiatry 2005; 66(11): 1362–6PubMedCrossRef Volavka J, Czobor P, Citrome L, et al. Efficacy of aripiprazole against hostility in schizophrenia and schizoaffective disorder: data from 5 double-blind studies. J Clin Psychiatry 2005; 66(11): 1362–6PubMedCrossRef
53.
go back to reference Marder SR, West B, Lau GS, et al. Aripiprazole effects in patients with acute schizophrenia experiencing higher or lower agitation: a post hoc analysis of 4 randomized, placebo-controlled clinical trials. J Clin Psychiatry 2007; 68(5): 662–8PubMedCrossRef Marder SR, West B, Lau GS, et al. Aripiprazole effects in patients with acute schizophrenia experiencing higher or lower agitation: a post hoc analysis of 4 randomized, placebo-controlled clinical trials. J Clin Psychiatry 2007; 68(5): 662–8PubMedCrossRef
54.
go back to reference Citrome L, Casey DE, Daniel DG, et al. Effects of adjunctive valproate on hostility in patients with schizophrenia receiving olanzapine or risperidone: a double-blind multi-center study. Psychiatr Serv 2004; 55(3): 290–4PubMedCrossRef Citrome L, Casey DE, Daniel DG, et al. Effects of adjunctive valproate on hostility in patients with schizophrenia receiving olanzapine or risperidone: a double-blind multi-center study. Psychiatr Serv 2004; 55(3): 290–4PubMedCrossRef
55.
go back to reference Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005; 353(12): 1209–23PubMedCrossRef Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005; 353(12): 1209–23PubMedCrossRef
56.
go back to reference Swanson JW, Swartz MS, Van Dorn RA, et al. Comparison of antipsychotic medication effects on reducing violence in people with schizophrenia. Br J Psychiatry 2008; 193(1): 37–43PubMedCrossRef Swanson JW, Swartz MS, Van Dorn RA, et al. Comparison of antipsychotic medication effects on reducing violence in people with schizophrenia. Br J Psychiatry 2008; 193(1): 37–43PubMedCrossRef
57.
go back to reference Swanson JW, Van Dorn RA, Swartz MS, et al. Alternative pathways to violence in persons with schizophrenia: the role of childhood antisocial behavior problems. Law Hum Behav 2008; 32(3): 228–40PubMedCrossRef Swanson JW, Van Dorn RA, Swartz MS, et al. Alternative pathways to violence in persons with schizophrenia: the role of childhood antisocial behavior problems. Law Hum Behav 2008; 32(3): 228–40PubMedCrossRef
58.
go back to reference Volavka J, Citrome L. Pathways to aggression in schizophrenia affect results of treatment. Schizophr Bull 2011; 37(5): 921–9PubMedCrossRef Volavka J, Citrome L. Pathways to aggression in schizophrenia affect results of treatment. Schizophr Bull 2011; 37(5): 921–9PubMedCrossRef
59.
go back to reference Hollander E, Allen A, Lopez RP, et al. A preliminary double-blind, placebo-controlled trial of divalproex sodium in borderline personality disorder. J Clin Psychiatry 2001; 62(3): 199–203PubMedCrossRef Hollander E, Allen A, Lopez RP, et al. A preliminary double-blind, placebo-controlled trial of divalproex sodium in borderline personality disorder. J Clin Psychiatry 2001; 62(3): 199–203PubMedCrossRef
60.
go back to reference Donovan SJ, Stewart JW, Nunes EV, et al. Divalproex treatment for youth with explosive temper and mood lability: a double-blind, placebo controlled crossover design. Am J Psychiatry 2000; 157(6): 818–20PubMedCrossRef Donovan SJ, Stewart JW, Nunes EV, et al. Divalproex treatment for youth with explosive temper and mood lability: a double-blind, placebo controlled crossover design. Am J Psychiatry 2000; 157(6): 818–20PubMedCrossRef
61.
go back to reference Citrome L, Shope CB, Nolan KA, et al. Risperidone alone versus risperidone plus valproate in the treatment of patients with schizophrenia and hostility. Int Clin Psychopharmacol 2007; 22(6): 356–62PubMedCrossRef Citrome L, Shope CB, Nolan KA, et al. Risperidone alone versus risperidone plus valproate in the treatment of patients with schizophrenia and hostility. Int Clin Psychopharmacol 2007; 22(6): 356–62PubMedCrossRef
62.
go back to reference Sival RC, Haffmans PM, Jansen PA, et al. Sodium valproate in the treatment of aggressive behavior in patients with dementia: a randomized placebo controlled clinical trial. Int J Geriatr Psychiatry 2002; 17(6): 579–85PubMedCrossRef Sival RC, Haffmans PM, Jansen PA, et al. Sodium valproate in the treatment of aggressive behavior in patients with dementia: a randomized placebo controlled clinical trial. Int J Geriatr Psychiatry 2002; 17(6): 579–85PubMedCrossRef
63.
go back to reference Tariot PN, Erb R, Podgorski CA, et al. Efficacy and tolerability of carbamazepine for agitation and aggression in dementia. Am J Psychiatry 1998; 155(1): 54–61PubMed Tariot PN, Erb R, Podgorski CA, et al. Efficacy and tolerability of carbamazepine for agitation and aggression in dementia. Am J Psychiatry 1998; 155(1): 54–61PubMed
64.
go back to reference Collins PJ, Larkin EP, Shubsachs AP. Lithium carbonate in chronic schizophrenia: a brief trial of lithium carbonate added to neuroleptics for treatment of resistant schizophrenic patients. Acta Psychiatr Scand 1991; 84(2): 150–4PubMedCrossRef Collins PJ, Larkin EP, Shubsachs AP. Lithium carbonate in chronic schizophrenia: a brief trial of lithium carbonate added to neuroleptics for treatment of resistant schizophrenic patients. Acta Psychiatr Scand 1991; 84(2): 150–4PubMedCrossRef
65.
go back to reference Sheard MH, Marini JL, Bridges CI, et al. The effect of lithium on impulsive aggressive behavior in man. Am J Psychiatry 1976; 133(12): 1409–13PubMed Sheard MH, Marini JL, Bridges CI, et al. The effect of lithium on impulsive aggressive behavior in man. Am J Psychiatry 1976; 133(12): 1409–13PubMed
66.
go back to reference Ratey JJ, Sorgi P, O’Driscoll GA, et al. Nadolol to treat ggression and psychiatric symptomatology in chronicpsychiatric inpatients: a double-blind, placebo-controlled study. J Clin Psychiatry 1992; 53(2): 41–6PubMed Ratey JJ, Sorgi P, O’Driscoll GA, et al. Nadolol to treat ggression and psychiatric symptomatology in chronicpsychiatric inpatients: a double-blind, placebo-controlled study. J Clin Psychiatry 1992; 53(2): 41–6PubMed
67.
go back to reference Alpert M, Allan ER, Citrome L, et al. A double-blind, placebo-controlled study of adjunctive nadolol in the management of violent psychiatric patients. Psychopharmacol Bull 1990; 26(3): 367–71PubMed Alpert M, Allan ER, Citrome L, et al. A double-blind, placebo-controlled study of adjunctive nadolol in the management of violent psychiatric patients. Psychopharmacol Bull 1990; 26(3): 367–71PubMed
68.
go back to reference Caspi N, Modai I, Barak P, et al. Pindolol augmentation in aggressive schizophrenic patients: a double-blind crossover randomized study. Int Clin Psychopharmacol 2001; 16(2): 111–5PubMedCrossRef Caspi N, Modai I, Barak P, et al. Pindolol augmentation in aggressive schizophrenic patients: a double-blind crossover randomized study. Int Clin Psychopharmacol 2001; 16(2): 111–5PubMedCrossRef
69.
go back to reference Karson CN, Weinberger DR, Bigelow L, et al. Clonazepam treatment of chronic schizophrenia: negative results in a double-blind, placebo-controlled trial. Am J Psychiatry 1982; 139(12): 1627–8PubMed Karson CN, Weinberger DR, Bigelow L, et al. Clonazepam treatment of chronic schizophrenia: negative results in a double-blind, placebo-controlled trial. Am J Psychiatry 1982; 139(12): 1627–8PubMed
70.
go back to reference Vartiainen H, Tiihonen J, Putkonen A, et al. Citalopram, a selective serotonin reuptake inhibitor, in the treatment of aggression in schizophrenia. Acta Psychiatr Scand 1995; 91(5): 348–51PubMedCrossRef Vartiainen H, Tiihonen J, Putkonen A, et al. Citalopram, a selective serotonin reuptake inhibitor, in the treatment of aggression in schizophrenia. Acta Psychiatr Scand 1995; 91(5): 348–51PubMedCrossRef
71.
go back to reference Coccaro EF, Kavoussi RJ. Fluoxetine and impulsive aggressive behavior in personality-disordered subjects. Arch Gen Psychiatry 1997; 54(12): 1081–8PubMedCrossRef Coccaro EF, Kavoussi RJ. Fluoxetine and impulsive aggressive behavior in personality-disordered subjects. Arch Gen Psychiatry 1997; 54(12): 1081–8PubMedCrossRef
72.
go back to reference Strous RD, Ritsner MS, Adler S, et al. Improvement of aggressive behavior and quality of life impairment following S-adenosyl-methionine (SAM-e) augmentation in schizophrenia. Eur Neuropsychopharmacol 2009; 19(1): 14–22PubMedCrossRef Strous RD, Ritsner MS, Adler S, et al. Improvement of aggressive behavior and quality of life impairment following S-adenosyl-methionine (SAM-e) augmentation in schizophrenia. Eur Neuropsychopharmacol 2009; 19(1): 14–22PubMedCrossRef
73.
go back to reference Citrome L, Levine J, Allingham B. Changes in use of valproate and other mood stabilizers for patients with schizophrenia from 1994 to 1998. Psychiatr Serv 2000; 51(5): 634–8PubMedCrossRef Citrome L, Levine J, Allingham B. Changes in use of valproate and other mood stabilizers for patients with schizophrenia from 1994 to 1998. Psychiatr Serv 2000; 51(5): 634–8PubMedCrossRef
74.
go back to reference Citrome L. Adjunctive lithium and anticonvulsants for the treatment of schizophrenia: what is the evidence? Expert Rev Neurother 2009; 9(1): 55–71PubMedCrossRef Citrome L. Adjunctive lithium and anticonvulsants for the treatment of schizophrenia: what is the evidence? Expert Rev Neurother 2009; 9(1): 55–71PubMedCrossRef
75.
go back to reference Huband N, Ferriter M, Nathan R, et al. Antiepileptics for aggression and associated impulsivity. Cochrane DatabaseSyst Rev 2010 Feb 17; (2): CD003499 Huband N, Ferriter M, Nathan R, et al. Antiepileptics for aggression and associated impulsivity. Cochrane DatabaseSyst Rev 2010 Feb 17; (2): CD003499
76.
go back to reference Volavka J, Citrome L. Atypical antipsychotics in the treatment of the persistently aggressive psychotic patient: methodologicalconcerns. Schizophr Res 1999; 35 Suppl. : S23–33PubMedCrossRef Volavka J, Citrome L. Atypical antipsychotics in the treatment of the persistently aggressive psychotic patient: methodologicalconcerns. Schizophr Res 1999; 35 Suppl. : S23–33PubMedCrossRef
77.
go back to reference Alia-Klein N, O’Rourke TM, Goldstein RZ, et al. Insight into illness and adherence to psychotropic medications are separately associated with violence severity in a forensic sample. Aggress Behav 2007; 33(1): 86–96PubMedCrossRef Alia-Klein N, O’Rourke TM, Goldstein RZ, et al. Insight into illness and adherence to psychotropic medications are separately associated with violence severity in a forensic sample. Aggress Behav 2007; 33(1): 86–96PubMedCrossRef
78.
go back to reference Arango C, Bombín I, González-Salvador T, et al. Randomised clinical trial comparing oral versus depot formulations of zuclopenthixol in patients with schizophrenia and previous violence. Eur Psychiatry 2006; 21(1): 34–40PubMedCrossRef Arango C, Bombín I, González-Salvador T, et al. Randomised clinical trial comparing oral versus depot formulations of zuclopenthixol in patients with schizophrenia and previous violence. Eur Psychiatry 2006; 21(1): 34–40PubMedCrossRef
79.
go back to reference Kessler RC, Coccaro EF, Fava M, et al. The prevalence and correlates of DSM-IV intermittent explosive disorder in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2006; 63(6): 669–78PubMedCrossRef Kessler RC, Coccaro EF, Fava M, et al. The prevalence and correlates of DSM-IV intermittent explosive disorder in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2006; 63(6): 669–78PubMedCrossRef
80.
go back to reference Coccaro EF, Lee RJ, Kavoussi RJ. A double-blind, randomized, placebo-controlled trial of fluoxetine in patients with intermittent explosive disorder. J Clin Psychiatry 2009; 70(5): 653–62PubMedCrossRef Coccaro EF, Lee RJ, Kavoussi RJ. A double-blind, randomized, placebo-controlled trial of fluoxetine in patients with intermittent explosive disorder. J Clin Psychiatry 2009; 70(5): 653–62PubMedCrossRef
81.
go back to reference Hollander E, Tracy KA, Swann AC, et al. Divalproex in the treatment of impulsive aggression: efficacy in Cluster B personality disorders. Neuropsychopharmacology 2003; 28(6): 1186–97PubMed Hollander E, Tracy KA, Swann AC, et al. Divalproex in the treatment of impulsive aggression: efficacy in Cluster B personality disorders. Neuropsychopharmacology 2003; 28(6): 1186–97PubMed
82.
go back to reference Hollander E, Swann AC, Coccaro EF, et al. Impact of trait impulsivity and state aggression on divalproex versus placebo response in borderline personality disorder. Am J Psychiatry 2005; 162(3): 621–4PubMedCrossRef Hollander E, Swann AC, Coccaro EF, et al. Impact of trait impulsivity and state aggression on divalproex versus placebo response in borderline personality disorder. Am J Psychiatry 2005; 162(3): 621–4PubMedCrossRef
84.
go back to reference Swann AC, Bowden CL, Calabrese JR, et al. Pattern of response to divalproex, lithium, or placebo in four naturalistic subtypes of mania. Neuropsychopharmacology 2002; 26(4): 530–6PubMedCrossRef Swann AC, Bowden CL, Calabrese JR, et al. Pattern of response to divalproex, lithium, or placebo in four naturalistic subtypes of mania. Neuropsychopharmacology 2002; 26(4): 530–6PubMedCrossRef
Metadata
Title
Pharmacological Management of Acute and Persistent Aggression in Forensic Psychiatry Settings
Authors
Dr Leslie Citrome, MD, MPH
Jan Volavka
Publication date
01-12-2011
Publisher
Springer International Publishing
Published in
CNS Drugs / Issue 12/2011
Print ISSN: 1172-7047
Electronic ISSN: 1179-1934
DOI
https://doi.org/10.2165/11596930-000000000-00000

Other articles of this Issue 12/2011

CNS Drugs 12/2011 Go to the issue

Acknowledgments

Acknowledgement

Adis Drug Profile

Tetrabenazine